Literature DB >> 30363854

Pramipexole-Induced Reversible Heart Failure.

Matveï Apraxine1, Agnes Pasquet2, Anne Jeanjean3.   

Abstract

Entities:  

Keywords:  Parkinson; heart failure; pramipexole

Year:  2014        PMID： 30363854      PMCID： PMC6182994          DOI： 10.1002/mdc3.12096

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  7 in total

1.  The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease.

Authors:  M Mostafa Mokhles; Gianluca Trifirò; Jeanne P Dieleman; Mendel D Haag; Eva M van Soest; Katia M C Verhamme; Giampiero Mazzaglia; Ron Herings; Cynthia de Luise; Douglas Ross; Guy Brusselle; Annamaria Colao; Willem Haverkamp; Rene Schade; Guy van Camp; Renzo Zanettini; Miriam C J M Sturkenboom
Journal:  Pharmacol Res       Date:  2011-11-23       Impact factor: 7.658

2.  Risk of heart failure associated with dopamine agonists: a nested case-control study.

Authors:  P H Hsieh; F Y Hsiao
Journal:  Drugs Aging       Date:  2013-09       Impact factor: 3.923

3.  Dopamine agonist use and the risk of heart failure.

Authors:  Christel Renoux; Sophie Dell'Aniello; James M Brophy; Samy Suissa
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-11-23       Impact factor: 2.890

4.  Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.

Authors:  M F Piercey; W E Hoffmann; M W Smith; D K Hyslop
Journal:  Eur J Pharmacol       Date:  1996-09-19       Impact factor: 4.432

5.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Authors:  John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher
Journal:  Eur Heart J       Date:  2012-05-19       Impact factor: 29.983

6.  Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain.

Authors:  O Chernoloz; M El Mansari; P Blier
Journal:  Neuropsychopharmacology       Date:  2008-08-06       Impact factor: 7.853

Review 7.  Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.

Authors:  Angelo Antonini; Werner Poewe
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182
  7 in total
  3 in total

1.  Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson's Disease Patients: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Renato De Vecchis; Claudio Cantatrione; Damiana Mazzei; Cesare Baldi; Marco Di Maio
Journal:  J Clin Med Res       Date:  2016-05-25

Review 2.  Non-Coding RNAs in the Brain-Heart Axis: The Case of Parkinson's Disease.

Authors:  Shubhra Acharya; Antonio Salgado-Somoza; Francesca Maria Stefanizzi; Andrew I Lumley; Lu Zhang; Enrico Glaab; Patrick May; Yvan Devaux
Journal:  Int J Mol Sci       Date:  2020-09-06       Impact factor: 5.923

Review 3.  Cardiac Changes in Parkinson's Disease: Lessons from Clinical and Experimental Evidence.

Authors:  Lorena Cuenca-Bermejo; Pilar Almela; Javier Navarro-Zaragoza; Emiliano Fernández Villalba; Ana-María González-Cuello; María-Luisa Laorden; María-Trinidad Herrero
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.